Overview


According to FutureWise analysis the market for anticancer drugs in 2023 is US$ 167.93 billion, and is expected to reach US$ 302.18 billion by 2031 at a CAGR of 7.60%.

Anticancer drugs, also known as antineoplastic drugs, are drugs that are effective in the treatment of cancerous disease. These drugs disrupt the growth and division of cancer cells, ultimately slowing down or eliminating cancer progression. Anticancer drugs have diverse administration methods, including oral pills, intravenous injections, and can also be integrated into combination therapies alongside treatments like surgery, radiation therapy, or immunotherapy. They are an essential component of cancer treatment. They can be used at different stages of cancer management, including shrinking tumours before surgery, destroying remaining cancer cells after surgery, or managing advanced and metastatic cancer. The selection and use of specific anticancer drugs depend on the type of cancer, its stage, the patient's overall health, and the treatment goals.

The anticancer drug market refers to the global pharmaceutical industry segment dedicated to the research, development, manufacturing, and distribution of medications specifically designed to treat various types of cancer. This market encompasses a wide range of therapies, including traditional chemotherapy agents, targeted therapies, immunotherapies, and other innovative treatments to combat cancer at different stages.

FutureWise Market Research has published a report that provides an insightful analysis of Anti-Cancer Drug Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analyst’s projects that Anti-Cancer Drug Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc
  • Bayer AG
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited
  • MerckCo., Inc.
  • Celgene Corporation
  • Amgen Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Anti-Cancer Drug Market 

  • Bayer AG announced that they agreed to acquire Noria Therapeutics Inc. and PSMA Therapeutics Inc in June 2021, giving Bayer exclusive rights to the company’s investigational compound through this agreement. 

 

  • Sanofi announced that they had acquired Tidal Therapeutics, a pre-clinical biotech company responsible for developing an mRNA-based research platform, in April 2021. This acquisition will help Sanofi leverage a new technology platform to enhance its research capabilities in the field of oncology, immunology, and other disease 

 

The rising cancer incidence globally has significantly driven the Anticancer drug markets. As the number of cancer cases increases, the demand for effective and innovative treatment is growing to combat the disease. The world's aging population is contributing to the increased prevalence of cancer, as cancer intends to be higher in older individuals, fueling market growth. Awareness programs run by private and public organization and funding for research and development and clinical trials for drugs by the government is also creating new opportunities for market growth. Technological advancements in medical research, genomics, and biotechnology have led to a deeper understanding of the drugs and the disease, again bolstering the market's revenue growth. 

However, specific barriers can be seen which hamper the market growth which, includes reimbursement challenges where healthcare systems and insurance providers face challenges; ethical and socials concern is one of the most significant factors affecting the market growth as the cost and availability of cancer treatments can raise the issue in the lower income regions and countries with limited access to advanced healthcare. With the emerging time and situation, there may be an increase or decrease in the factors affecting the market growth.

By Drug Type

  • Cytotoxic Drugs
    • Alkylating Agents
    • Antimetabolites
    • Others
  • Targeted Drugs
    • Monoclonal Antibodies
    • Tyrosine Kinase Inhibitors
    • Others
  • Hormonal Drugs

By Therapy Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherap
  • Others

By Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Leukemia
  • Colorectal Cancer
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America accounted for the largest share and is foreseeing to maintain its dominance in the upcoming future owing to the presence of a comprehensive patient population, strong presence of key players, well-developed healthcare infrastructure, ease of drug availability, favourable reimbursement policies in the healthcare system, innovation activities and higher adoption of advanced therapeutics, a higher number of research and development. Asia-Pacific is expected to grow at the highest CAGR, owing to an increase in the number of cancer-affected populations and a rise in awareness related to different cancers.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the of Anti-Cancer Drug Market By Drug therapy, By Cancer Type, By Therapy type, and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represents in format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Anticancer Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anticancer Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Anticancer Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Anticancer Drugs Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cytotoxic Drugs
         1.1. Alkylating Agents
         1.2. Antimetabolites
         1.3. Others
        2. Targeted Drugs
         2.1. Monoclonal Antibodies
         2.2. Tyrosine Kinase Inhibitors
         2.3. Others
        3. Hormonal Drugs

  • 8.   Anticancer Drugs Market, By Therapy Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Chemotherapy
        2. Targeted Therapy
        3. Immunotherapy
        4. Others

  • 9.   Anticancer Drugs Market, By Cancer Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Lung Cancer
        2. Breast Cancer
        3. Leukemia
        4. Colorectal Cancer
        5. Others

  • 10.   North America Anticancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Anticancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Anticancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Anticancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. F. Hoffmann-La Roche Ltd
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Eli Lilly and Company
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Novartis AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Pfizer Inc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Bayer AGr
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. AstraZeneca
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Takeda Pharmaceutical Company Limited
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. MerckCo., Inc..
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Celgene Corporation
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Amgen Inc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients